ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have been given an average rating of “Moderate Buy” by the eight analysts that are currently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $107.3333.

ANIP has been the topic of a number of recent research reports. Weiss Ratings raised ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, June 23rd. Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Finally, Zacks Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th.

Insider Activity

In other ANI Pharmaceuticals news, Director Thomas Haughey sold 2,000 shares of ANI Pharmaceuticals stock in a transaction on Monday, June 8th. The stock was sold at an average price of $80.88, for a total transaction of $161,760.00. Following the completion of the transaction, the director directly owned 38,878 shares of the company’s stock, valued at approximately $3,144,452.64. This trade represents a 4.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Patrick D. Walsh sold 10,000 shares of the stock in a transaction dated Wednesday, May 13th. The stock was sold at an average price of $80.63, for a total transaction of $806,300.00. Following the sale, the director owned 38,432 shares of the company’s stock, valued at $3,098,772.16. This trade represents a 20.65% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 81,866 shares of company stock valued at $6,435,733. 8.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ANIP. Pacer Advisors Inc. grew its position in ANI Pharmaceuticals by 6.9% during the 1st quarter. Pacer Advisors Inc. now owns 85,467 shares of the specialty pharmaceutical company’s stock worth $6,572,000 after acquiring an additional 5,548 shares during the last quarter. Bank of America Corp DE boosted its stake in ANI Pharmaceuticals by 229.4% in the first quarter. Bank of America Corp DE now owns 150,532 shares of the specialty pharmaceutical company’s stock worth $11,576,000 after purchasing an additional 104,828 shares in the last quarter. Janus Henderson Group PLC boosted its stake in ANI Pharmaceuticals by 1,308.1% in the first quarter. Janus Henderson Group PLC now owns 109,552 shares of the specialty pharmaceutical company’s stock worth $8,425,000 after purchasing an additional 101,772 shares in the last quarter. California State Teachers Retirement System grew its holdings in shares of ANI Pharmaceuticals by 57.3% during the first quarter. California State Teachers Retirement System now owns 24,557 shares of the specialty pharmaceutical company’s stock worth $1,888,000 after purchasing an additional 8,946 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of ANI Pharmaceuticals by 1.5% during the first quarter. The Manufacturers Life Insurance Company now owns 9,577 shares of the specialty pharmaceutical company’s stock worth $736,000 after purchasing an additional 143 shares during the last quarter. 76.05% of the stock is owned by institutional investors and hedge funds.

ANI Pharmaceuticals Stock Performance

Shares of ANI Pharmaceuticals stock opened at $86.03 on Tuesday. The firm has a market capitalization of $1.96 billion, a PE ratio of 21.78 and a beta of 0.43. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.12 and a quick ratio of 2.52. The company’s fifty day moving average price is $81.00 and its two-hundred day moving average price is $79.44. ANI Pharmaceuticals has a 52-week low of $62.60 and a 52-week high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, topping analysts’ consensus estimates of $1.28 by $0.77. The company had revenue of $237.46 million during the quarter, compared to the consensus estimate of $207.63 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The firm’s revenue for the quarter was up 20.5% compared to the same quarter last year. During the same period last year, the firm earned $1.70 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, analysts expect that ANI Pharmaceuticals will post 8.03 EPS for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.